ELITE TEST BANK: CMDT
63RD ED. & 2026/2027
NURSING EXAM
BLUEPRINT
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Critical Action" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–28) Focus: 2026
AHA PREVENT, GOLD 'ABE', ADA AID Standards, MASLD Nomenclature, Texas
SB 1188, KDIGO 2026.
○ Section 2: Professional Simulation (Questions 29–58) Focus: Acute
Exacerbation Protocols, Sepsis Dynamic Resuscitation, JCAHO NPG 12, UT Austin
Clinical Scenarios.
○ Section 3: Grandmaster Synthesis (Questions 59–88) Focus: Multi-System
Failure, NRP 395L Quality Improvement, Automation Bias, Complex Delegation.
PART I: THE PRIMER
The "Welcome to the Big Leagues" Hook Welcome to the top tier of clinical practice. This test
bank is engineered with a singular, ruthless purpose: to intercept high-stakes professional errors
before they reach the bedside and to forge your academic knowledge into razor-sharp
professional intuition. By mastering these 88 high-caliber scenarios, you are replacing outdated
rote memorization with the dynamic, real-time clinical architecture required to lead in the
2026/2027 healthcare environment.
The "Critical Action" Cheat Sheet
Clinical Domain Legacy Standard 2026/2027 Redline Clinical Rationale
(Obsolete) Standard (Current)
AHA Dyslipidemia Pooled Cohort PREVENT-CVD Eliminates race;
Equations (10-yr risk). Calculator (10- & 30-yr integrates Social
risk). Deprivation Index (SDI)
and kidney metrics
(UACR). Early statin
initiation for high 30-yr
,Clinical Domain Legacy Standard 2026/2027 Redline Clinical Rationale
(Obsolete) Standard (Current)
risk.
GOLD COPD Group A, B, C, D; Group A, B, E A single moderate
step-up after 2 failures. Classification. exacerbation mandates
Group E classification
and immediate
escalation to dual
LABA/LAMA therapy to
prevent 30-day MACE.
Sepsis Resuscitation Mandatory 30 mL/kg Dynamic Fluid Static boluses cause
fluid bolus. Assessment. ARDS. Use pulse
pressure variation
(PPV) or passive leg
raise (PLR) to guide
fluids. Escalate to
pressors early.
ADA Diabetes Tech Step-therapy; Automated Insulin AID is the absolute
C-peptide Delivery (AID). preferred standard for
prerequisites. all T1D and
insulin-dependent T2D
at diagnosis. Removes
access barriers.
JCAHO Staffing Headcount/Financial NPG 12 Acuity-Based The Nurse Executive is
staffing matrices. Staffing. federally mandated to
match staff
competencies directly
to patient acuity.
Ensures 24/7 RN
oversight.
Texas SB 1188 Unregulated Ambient Mandatory Patient Practitioners using AI
AI use. Disclosure. for
documentation/diagnos
tics must disclose its
use and hold total
liability for hallucinated
data.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: According to the 2026 AHA Dyslipidemia Guidelines, which novel risk assessment tool is
the FIRST choice for evaluating a 35-year-old patient for primary prevention of atherosclerotic
cardiovascular disease (ASCVD)? A) The Pooled Cohort Equations (PCE) to estimate 10-year
risk. B) The PREVENT-CVD calculator to estimate 10-year and 30-year risk. C) The
Framingham Risk Score targeting solely LDL cholesterol. D) The AHA/ACC 2018 ASCVD Risk
,Estimator Plus.
● The Answer: B (The PREVENT-CVD calculator to estimate 10-year and 30-year risk.)
● Distractor Analysis:
○ A is incorrect: The PCE is an outdated legacy tool retired in the 2026 guidelines.
○ C is incorrect: Framingham is obsolete for modern cardiovascular-kidney-metabolic
(CKM) risk assessment.
○ D is incorrect: The 2018 estimator has been explicitly replaced by the PREVENT
equations.
The Mentor's Analysis: The 2026 standard views cardiovascular disease as a lifelong
cumulative exposure. You cannot wait until a patient is 50 to calculate risk. By utilizing the
PREVENT calculator to assess 30-year risk at age 35, you intercept plaque burden decades
before a catastrophic event. Professional Intuition: Always project risk longitudinally; early
lipid-lowering is secondary prevention against future infrastructure collapse.
Q2: A patient is newly diagnosed with Type 1 Diabetes. Based on the 2026 ADA Standards of
Care, which insulin delivery modality is the MOST APPROPRIATE INITIAL recommendation?
A) Multiple daily injections (MDI) utilizing NPH and regular insulin. B) Continuous subcutaneous
insulin infusion (CSII) after proving compliance with MDI for 6 months. C) An Automated Insulin
Delivery (AID) system. D) Inhaled prandial insulin combined with an oral GLP-1 receptor
agonist.
● The Answer: C (An Automated Insulin Delivery (AID) system.)
● Distractor Analysis:
○ A is incorrect: NPH/Regular is a dangerous legacy regimen that maximizes
hypoglycemia risk.
○ B is incorrect: The 2026 ADA explicitly states there should be no step-therapy or
required duration of insulin treatment before initiating AID.
○ D is incorrect: While GLP-1s have a role in specific metabolic profiles, AID is the
definitive baseline standard of care for T1D.
The Mentor's Analysis: Step-therapy in T1D is an artificial barrier that harms patients. The
2026 ADA guidelines recognize that AID systems prevent extreme glycemic variability right at
diagnosis. Professional Intuition: Technology is not a reward for compliance; it is the baseline
requirement for physiological stability.
Q3: Under the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines,
how is a patient reclassified if they experience a SINGLE moderate exacerbation not requiring
hospitalization? A) They remain in Group A but require an inhaled corticosteroid (ICS). B) They
are placed in Group B with optimization of monotherapy. C) They are instantly reclassified to
Group E, mandating dual LAMA/LABA therapy. D) They are classified as Group C and require
chronic systemic corticosteroids.
● The Answer: C (They are instantly reclassified to Group E, mandating dual LAMA/LABA
therapy.)
● Distractor Analysis:
○ A is incorrect: ICS monotherapy is strictly contraindicated in COPD.
○ B is incorrect: A single moderate exacerbation is now recognized as a critical
destabilization event, moving them out of Group B.
○ D is incorrect: Group C and D classifications were abandoned in favor of the ABE
model.
The Mentor's Analysis: We no longer wait for a patient to fail twice before escalating care. A
single exacerbation fundamentally alters the cardiovascular and pulmonary risk trajectory for the
next 30 days. Professional Intuition: Treat the first strike as the final warning. Escalate to dual
, bronchodilation instantly to prevent the next, potentially fatal, decompensation.
Q4: In 2026, the nomenclature for non-alcoholic fatty liver disease (NAFLD) was officially
changed. Which term is MOST APPROPRIATE for a nurse practitioner to use in clinical
documentation for a patient with hepatic steatosis driven by metabolic syndrome? A)
Non-alcoholic steatohepatitis (NASH). B) Metabolic dysfunction-associated steatotic liver
disease (MASLD). C) Cryptogenic steatotic liver disease. D) Benign hepatic steatosis.
● The Answer: B (Metabolic dysfunction-associated steatotic liver disease (MASLD).)
● Distractor Analysis:
○ A is incorrect: NASH is stigmatizing and clinically inaccurate; it has been replaced
by MASH.
○ C is incorrect: Cryptogenic is reserved only for patients with no identifiable
metabolic or alcohol-related cause.
○ D is incorrect: Steatosis driven by metabolic syndrome is never "benign" and
requires aggressive cardiometabolic intervention.
The Mentor's Analysis: Words dictate clinical pathways. The shift to MASLD removes the
stigma of "alcoholic" terminology while correctly identifying the true enemy: metabolic
dysfunction. Professional Intuition: When you document MASLD, you instantly trigger the
systemic cardiometabolic workflow (GLP-1s, statins, PREVENT-CVD).
Q5: The 2026 American College of Gastroenterology (ACG) guidelines dictate a fundamental
shift in the primary treatment of Helicobacter pylori. Which regimen is the FIRST-LINE standard
for a treatment-naïve patient with unknown antibiotic susceptibility? A) 7-day standard
PPI-clarithromycin triple therapy. B) 14-day optimized Bismuth Quadruple Therapy (BQT). C)
10-day sequential therapy utilizing levofloxacin. D) 14-day high-dose amoxicillin monotherapy.
● The Answer: B (14-day optimized Bismuth Quadruple Therapy (BQT).)
● Distractor Analysis:
○ A is incorrect: PPI-clarithromycin triple therapy is expressly forbidden unless
susceptibility testing confirms clarithromycin sensitivity, due to massive resistance
rates.
○ C is incorrect: Levofloxacin should only be used if confirmed by antimicrobial
susceptibility testing.
○ D is incorrect: Amoxicillin is used in dual therapy with vonoprazan, never as
monotherapy for H. pylori.
The Mentor's Analysis: Macrolide resistance has broken the old algorithms. Using empiric
clarithromycin in 2026 is clinical negligence. Bismuth quadruple therapy bypasses standard
resistance mechanisms. Professional Intuition: Never guess with antibiotics in GI eradication.
If you lack resistance data, hit it with optimized BQT or Vonoprazan dual therapy.
Q6: Under the Texas SB 1188 (2025/2026) mandate regarding "Ambient AI" in the clinical
setting, what is the IMMEDIATE legal responsibility of the practitioner utilizing an AI scribe for
diagnostic assistance? A) Upload the patient's data to a decentralized blockchain for anonymity.
B) Provide explicit, plain-language disclosure to the patient that AI is being used. C) Have a
secondary physician co-sign the AI-generated note within 72 hours. D) Use "dark patterns" in
the consent form to secure rapid data usage rights.
● The Answer: B (Provide explicit, plain-language disclosure to the patient that AI is being
used.)
● Distractor Analysis:
○ A is incorrect: Blockchain is not a legal mandate under SB 1188.
○ C is incorrect: The practitioner using the AI must review and take ownership of the
note; a secondary physician is not mandated.
63RD ED. & 2026/2027
NURSING EXAM
BLUEPRINT
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Critical Action" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–28) Focus: 2026
AHA PREVENT, GOLD 'ABE', ADA AID Standards, MASLD Nomenclature, Texas
SB 1188, KDIGO 2026.
○ Section 2: Professional Simulation (Questions 29–58) Focus: Acute
Exacerbation Protocols, Sepsis Dynamic Resuscitation, JCAHO NPG 12, UT Austin
Clinical Scenarios.
○ Section 3: Grandmaster Synthesis (Questions 59–88) Focus: Multi-System
Failure, NRP 395L Quality Improvement, Automation Bias, Complex Delegation.
PART I: THE PRIMER
The "Welcome to the Big Leagues" Hook Welcome to the top tier of clinical practice. This test
bank is engineered with a singular, ruthless purpose: to intercept high-stakes professional errors
before they reach the bedside and to forge your academic knowledge into razor-sharp
professional intuition. By mastering these 88 high-caliber scenarios, you are replacing outdated
rote memorization with the dynamic, real-time clinical architecture required to lead in the
2026/2027 healthcare environment.
The "Critical Action" Cheat Sheet
Clinical Domain Legacy Standard 2026/2027 Redline Clinical Rationale
(Obsolete) Standard (Current)
AHA Dyslipidemia Pooled Cohort PREVENT-CVD Eliminates race;
Equations (10-yr risk). Calculator (10- & 30-yr integrates Social
risk). Deprivation Index (SDI)
and kidney metrics
(UACR). Early statin
initiation for high 30-yr
,Clinical Domain Legacy Standard 2026/2027 Redline Clinical Rationale
(Obsolete) Standard (Current)
risk.
GOLD COPD Group A, B, C, D; Group A, B, E A single moderate
step-up after 2 failures. Classification. exacerbation mandates
Group E classification
and immediate
escalation to dual
LABA/LAMA therapy to
prevent 30-day MACE.
Sepsis Resuscitation Mandatory 30 mL/kg Dynamic Fluid Static boluses cause
fluid bolus. Assessment. ARDS. Use pulse
pressure variation
(PPV) or passive leg
raise (PLR) to guide
fluids. Escalate to
pressors early.
ADA Diabetes Tech Step-therapy; Automated Insulin AID is the absolute
C-peptide Delivery (AID). preferred standard for
prerequisites. all T1D and
insulin-dependent T2D
at diagnosis. Removes
access barriers.
JCAHO Staffing Headcount/Financial NPG 12 Acuity-Based The Nurse Executive is
staffing matrices. Staffing. federally mandated to
match staff
competencies directly
to patient acuity.
Ensures 24/7 RN
oversight.
Texas SB 1188 Unregulated Ambient Mandatory Patient Practitioners using AI
AI use. Disclosure. for
documentation/diagnos
tics must disclose its
use and hold total
liability for hallucinated
data.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: According to the 2026 AHA Dyslipidemia Guidelines, which novel risk assessment tool is
the FIRST choice for evaluating a 35-year-old patient for primary prevention of atherosclerotic
cardiovascular disease (ASCVD)? A) The Pooled Cohort Equations (PCE) to estimate 10-year
risk. B) The PREVENT-CVD calculator to estimate 10-year and 30-year risk. C) The
Framingham Risk Score targeting solely LDL cholesterol. D) The AHA/ACC 2018 ASCVD Risk
,Estimator Plus.
● The Answer: B (The PREVENT-CVD calculator to estimate 10-year and 30-year risk.)
● Distractor Analysis:
○ A is incorrect: The PCE is an outdated legacy tool retired in the 2026 guidelines.
○ C is incorrect: Framingham is obsolete for modern cardiovascular-kidney-metabolic
(CKM) risk assessment.
○ D is incorrect: The 2018 estimator has been explicitly replaced by the PREVENT
equations.
The Mentor's Analysis: The 2026 standard views cardiovascular disease as a lifelong
cumulative exposure. You cannot wait until a patient is 50 to calculate risk. By utilizing the
PREVENT calculator to assess 30-year risk at age 35, you intercept plaque burden decades
before a catastrophic event. Professional Intuition: Always project risk longitudinally; early
lipid-lowering is secondary prevention against future infrastructure collapse.
Q2: A patient is newly diagnosed with Type 1 Diabetes. Based on the 2026 ADA Standards of
Care, which insulin delivery modality is the MOST APPROPRIATE INITIAL recommendation?
A) Multiple daily injections (MDI) utilizing NPH and regular insulin. B) Continuous subcutaneous
insulin infusion (CSII) after proving compliance with MDI for 6 months. C) An Automated Insulin
Delivery (AID) system. D) Inhaled prandial insulin combined with an oral GLP-1 receptor
agonist.
● The Answer: C (An Automated Insulin Delivery (AID) system.)
● Distractor Analysis:
○ A is incorrect: NPH/Regular is a dangerous legacy regimen that maximizes
hypoglycemia risk.
○ B is incorrect: The 2026 ADA explicitly states there should be no step-therapy or
required duration of insulin treatment before initiating AID.
○ D is incorrect: While GLP-1s have a role in specific metabolic profiles, AID is the
definitive baseline standard of care for T1D.
The Mentor's Analysis: Step-therapy in T1D is an artificial barrier that harms patients. The
2026 ADA guidelines recognize that AID systems prevent extreme glycemic variability right at
diagnosis. Professional Intuition: Technology is not a reward for compliance; it is the baseline
requirement for physiological stability.
Q3: Under the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines,
how is a patient reclassified if they experience a SINGLE moderate exacerbation not requiring
hospitalization? A) They remain in Group A but require an inhaled corticosteroid (ICS). B) They
are placed in Group B with optimization of monotherapy. C) They are instantly reclassified to
Group E, mandating dual LAMA/LABA therapy. D) They are classified as Group C and require
chronic systemic corticosteroids.
● The Answer: C (They are instantly reclassified to Group E, mandating dual LAMA/LABA
therapy.)
● Distractor Analysis:
○ A is incorrect: ICS monotherapy is strictly contraindicated in COPD.
○ B is incorrect: A single moderate exacerbation is now recognized as a critical
destabilization event, moving them out of Group B.
○ D is incorrect: Group C and D classifications were abandoned in favor of the ABE
model.
The Mentor's Analysis: We no longer wait for a patient to fail twice before escalating care. A
single exacerbation fundamentally alters the cardiovascular and pulmonary risk trajectory for the
next 30 days. Professional Intuition: Treat the first strike as the final warning. Escalate to dual
, bronchodilation instantly to prevent the next, potentially fatal, decompensation.
Q4: In 2026, the nomenclature for non-alcoholic fatty liver disease (NAFLD) was officially
changed. Which term is MOST APPROPRIATE for a nurse practitioner to use in clinical
documentation for a patient with hepatic steatosis driven by metabolic syndrome? A)
Non-alcoholic steatohepatitis (NASH). B) Metabolic dysfunction-associated steatotic liver
disease (MASLD). C) Cryptogenic steatotic liver disease. D) Benign hepatic steatosis.
● The Answer: B (Metabolic dysfunction-associated steatotic liver disease (MASLD).)
● Distractor Analysis:
○ A is incorrect: NASH is stigmatizing and clinically inaccurate; it has been replaced
by MASH.
○ C is incorrect: Cryptogenic is reserved only for patients with no identifiable
metabolic or alcohol-related cause.
○ D is incorrect: Steatosis driven by metabolic syndrome is never "benign" and
requires aggressive cardiometabolic intervention.
The Mentor's Analysis: Words dictate clinical pathways. The shift to MASLD removes the
stigma of "alcoholic" terminology while correctly identifying the true enemy: metabolic
dysfunction. Professional Intuition: When you document MASLD, you instantly trigger the
systemic cardiometabolic workflow (GLP-1s, statins, PREVENT-CVD).
Q5: The 2026 American College of Gastroenterology (ACG) guidelines dictate a fundamental
shift in the primary treatment of Helicobacter pylori. Which regimen is the FIRST-LINE standard
for a treatment-naïve patient with unknown antibiotic susceptibility? A) 7-day standard
PPI-clarithromycin triple therapy. B) 14-day optimized Bismuth Quadruple Therapy (BQT). C)
10-day sequential therapy utilizing levofloxacin. D) 14-day high-dose amoxicillin monotherapy.
● The Answer: B (14-day optimized Bismuth Quadruple Therapy (BQT).)
● Distractor Analysis:
○ A is incorrect: PPI-clarithromycin triple therapy is expressly forbidden unless
susceptibility testing confirms clarithromycin sensitivity, due to massive resistance
rates.
○ C is incorrect: Levofloxacin should only be used if confirmed by antimicrobial
susceptibility testing.
○ D is incorrect: Amoxicillin is used in dual therapy with vonoprazan, never as
monotherapy for H. pylori.
The Mentor's Analysis: Macrolide resistance has broken the old algorithms. Using empiric
clarithromycin in 2026 is clinical negligence. Bismuth quadruple therapy bypasses standard
resistance mechanisms. Professional Intuition: Never guess with antibiotics in GI eradication.
If you lack resistance data, hit it with optimized BQT or Vonoprazan dual therapy.
Q6: Under the Texas SB 1188 (2025/2026) mandate regarding "Ambient AI" in the clinical
setting, what is the IMMEDIATE legal responsibility of the practitioner utilizing an AI scribe for
diagnostic assistance? A) Upload the patient's data to a decentralized blockchain for anonymity.
B) Provide explicit, plain-language disclosure to the patient that AI is being used. C) Have a
secondary physician co-sign the AI-generated note within 72 hours. D) Use "dark patterns" in
the consent form to secure rapid data usage rights.
● The Answer: B (Provide explicit, plain-language disclosure to the patient that AI is being
used.)
● Distractor Analysis:
○ A is incorrect: Blockchain is not a legal mandate under SB 1188.
○ C is incorrect: The practitioner using the AI must review and take ownership of the
note; a secondary physician is not mandated.
